3. Umbruch 4.4..2005 - Online Pot

Index 267
cannabinoid agonist 190, 219
cannabinoid ratio 259
cannabinoid tolerance 208
Cannabis indica 8
Cannabis sativa L. 236, 238, 244
caryophyllene 16
caspase 3 83, 92, 97
caspase 83
cat 187, 188
catalase 84
CB 1 agonist noladin ether 203
CB 1 antagonist 184, 194, 195
CB 1 deficient mouse 90, 99, 202,
203
CB 1 receptor 67, 84, 88, 90–92, 99,
184, 185, 189, 194, 195, 233
CB 1 receptor antagonist 185, 189
CB 1 –/– mouse 112, 118–125, 129
CB 1-knockout mouse 213
CB 1-selective antagonist 32
CB 2 activation 203
CB 2 agonist HU-308 203
CB 2 deficient mouse 203
CB 2 receptor 80, 87, 96–98, 100,
233
CB 2 receptor antagonist 189
CB 2$ signaling 203, 204
CB 2-selective cannabinoid receptor
ligand 34
central neuropathic pain (CNP) 247,
249, 251–253
cerebral ischemia 88, 90
charas 4, 6
chemotherapy 15
chemotherapy, ANV 192
chemotherapy, emetic episodes 183
chemovar 237, 239, 240
cholera 15
choreic movements 91
chronic refractory pain 247
chronic relapsing experimental
autoimmune encephalomyelitis
(CREAE) 98
cisplatin 183–185, 187–192
classification of cannabinoids 234
clone 239
closed head injury 80, 83, 90
cocaine 14
complex II deficiency 92
conditioned avoidance 18, 193
conditioned freezing 122
conditioned gaping 192, 193
conditioned rejection 195
conditioned rejection reaction 193
conditioned taste avoidance 193
constipation 12, 23
convulsion 10
copper/zinc superoxide dismutase 1
(SOD-1) 100
CP-55,940 27, 189
Crohn’s disease 15
Cryptotis parva 187
cyclophosphamide 194
ρ-cymene 16
cytotoxic levels of Ca 2+ 83
dandruff 16
demyelination 86, 97
depolarization-induced suppression
of inhibition (DSI) 128, 129
dexanabinol (HU-211) 82, 83, 90,
100, 142
diagnostic marker 75
diarrhea 13
dog 187, 188
dopamine 99
dose-response relationships of
cannabidiol, bell-shaped 53–55,
60
dronabinol 96, 185, 252
drug-discrimination 210
dysentery 11
dyskinetic state 93
dysmenorrhea 10, 13, 16
dystonia and cannabidiol 52, 98
dysuria 10
eczema 10, 15
edema 83
EDSS 250